BST Update
BST Position Update: January 31, 2014
January 31, 2014 . . . . BioLineRx (NASDAQ: BLRX) – Buy up to $3.30 BLRX is our most recent addition to the portfolio. But this isn’t the first time we’ve traded the stock. Many of you will recall we closed out a position in BLRX back in November for a solid 55% gain. Not […]
BST Position Update: January 14, 2014
January 14, 2014 . . . . Conatus Pharmaceuticals (NASDAQ: CNAT) – Hold Our most recent addition to the portfolio took off like a rocket last week. CNAT soared to a new high of $15.67 to give us an outstanding 148% peak gain. Not bad for just three weeks into the trade. And even though it has pulled […]
BST Position Update – December 30, 2013
December 30, 2013 ***Special Trade Update***Hey folks, With 2013 quickly drawing to a close, I’d like to take a few minutes to share my thoughts about a biotech stock that I’m particularly excited about for 2014. You see, if all goes as planned with a certain company’s leading drug candidate, its stock price could skyrocket […]
BST Position Update: December 17, 2013
December 17, 2013 . . . . Anacor Pharmaceuticals (NASDAQ: ANAC) – Sell ANAC has been an outstanding performer for the portfolio. After dropping to a low of $3.00 in February, the stock has increased more than five-fold in the past ten months. As a result, we’re now sitting on gains of 245%! With the […]
BST Position Update: November 21, 2013
November 21, 2013 . . . . BioLineRx (NASDAQ: BLRX) – Sell BLRX has been a great performer for the portfolio. As I write we’re sitting on a terrific 55% gain on the position. Not bad for a stock that lost more than half its value on one bad day in March. We fully expected the stock […]
BST Position Update: October 23, 2013
October 23, 2013 . . . . Prana Biotechnology (NASDAQ: PRAN) – Buy up to $4.40 Prana was just added to the portfolio last week. This exciting biotech is developing drugs for the treatment of neurological disorders. It’s leading drug candidate is PBT2, which is in phase 2 testing for Alzheimer’s (IMAGINE) and Huntington diseases […]
BST Position Update: September 27, 2013
September 27, 2013 . . . . Cyclacel Pharmaceuticals (NASDAQ: CYCC) – Hold Cyclacel is our latest addition to the portfolio. This fascinating biotech is pioneering orally available, small molecule drugs that target various phases of cell cycle control. The company’s leading drug candidate is sapacitabine, which has potential to treat both blood cancers and […]
BST Position Update: August 22, 2013
August 22, 2013 . . . . Vical (NASDAQ: VICL) – Sell Vical announced bad news last week. The company reported that its melanoma drug candidate, Allovectin, failed its phase 3 trial. And as a result, the stock dropped significantly on the news. With no upside catalysts on the horizon, Vical is likely doomed to […]
BST Position Update: August 6, 2013
August 6, 2013 . . . . ImmunoCellular Therapeutics (NYSE: IMUC) – Hold Our latest recommendation is off to a very fast start. After hitting a new intra-day high of $3.69 today, IMUC finished the day at $3.57 to give us a solid 28% gain on the position. Not bad for just eight trading days in the […]
BST Position Update: July 2, 2013
July 2, 2013 . . . . Halozyme Therapeutics (NASDAQ: HALO) – Hold HALO’s surging! Since hitting a low of $5.88 on June 24th, the biotech has climbed 34% to $7.88! And today it traded over $8.30 for the first time since mid-May. The stock’s jumping on good news for Herceptin SC. Herceptin SC is […]
